Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-05-29 00:00:00 ET · period of report 2024-05-27 · accession 0001787306-24-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-29 | 2024-05-27 | ARQT | Matsuda Masaru | See Remark | A - Grant | $0.00 | +4,875 | 190.3K | +3% | $0 | |
| 2024-05-29 | 2024-05-28 | ARQT | Matsuda Masaru | See Remark | S - Sale | $9.01 | -1,775 | 188.5K | -0.9% | -$16.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-27 | A | A | 4,875 | $0.00 | 190,283 | D | — | — | (F1) Represents performance stock units ("PSUs") initially granted on January 3, 2022 that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on May 27, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date. |
| 2 | Common | Common Stock | 2024-05-28 | S | D | 1,775 | $9.01 | 188,508 | D | — | — | (F3) The transaction was executed in multiple trades in prices ranging from $8.99 to $9.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |